Arcellx

Intangible assets: Arcellx’s D‑Domain binding architecture underpins both the ddCAR and ARC‑SparX platforms and is protected by a patent estate that, as of December 31, 2025, comprised dozens of issued patents and 100+ applications. Regulatory designations for anito‑cel include RMAT, Fast Track and Orphan in multiple myeloma.

These are meaningful but not bulletproof moats given rapid innovation around BCMA and alternative modalities. Switching costs: CAR‑T selection is highly physician‑ and center‑driven.

Once a center is trained and logistics embedded with a given manufacturer, friction to switch exists but is moderate; efficacy, safety, slot availability and payer processes dominate choice. Network effects: Limited. Authorized treatment center breadth helps distribution, but classic network effects are weak.

Cost and scale: Partnership with Kite confers scale in manufacturing and site enablement that most emerging biotechs lack, potentially improving reliability and access at launch. Efficient scale: Autologous CAR‑T markets are capacity‑constrained with limited ATCs and complex logistics, which can deter new entrants.

Overall, an emerging moat exists but remains unproven until commercial execution validates sustained differentiation.